Find Therapeutics, a biopharmaceutical company in the clinical stage, has started administering doses of FTX-101 in its phase 1 clinical trial involving healthy participants. FTX-101 is a novel therapeutic peptide that controls the Plexin...
Ionis Pharmaceuticals, Inc. revealed that the Committee for Medicinal Products for Human Use (CHMP) in the European Union (EU) has recommended the approval of Ionis' and AstraZeneca's Wainzua (eplontersen) for treating hereditary transthyretin...
Oculis Holding AG (Oculis) has sped up the enrollment of patients for the phase 3 DIAMOND clinical trials of OCS-01 eye drops in DME and expanded the DIAMOND programme committees with leading retina specialists worldwide. Significant advancement...
National Institutes of Health (NIH) showed that an mpox vaccine administered to teenagers was safe and produced the same level of antibody response as in adults. Young people are one of the demographics impacted by mpox in the ongoing Clade I mpox...
Cullinan Therapeutics, Inc., a biopharmaceutical company specializing in developing targeted therapies, confirmed FDA approval for their Investigational New Drug Application for CLN-978. This enables the global phase 1 clinical trial in the US for...
Annovis Bio Inc, based in Malvern, a company in the advanced stages of clinical drug development, revealed on October 10, 2024, the positive results of their meeting with the US Food and Drug Administration regarding transformative treatments for...
Hoth Therapeutics, Inc., a company in the clinical stage of biopharmaceuticals that specializes in creating new treatments, is excited to share the news of receiving a US patent for their cutting-edge Alzheimer's treatment, HT-ALZ...
OKYO Pharma Limited, a company in the clinical stage of biopharmaceutical development, is creating new treatments for inflammatory dry eye disease (DED) and neuropathic corneal pain (NCP). This billion-dollar market lacks FDA-approved therapy for...
Circle Pharma, Inc., a company focused on finding and creating new macrocycle therapies, disclosed that the initial group of patients has been given doses in the phase 1 study of CID-078, their groundbreaking oral cyclin A/B RxL inhibitor...
.webp)
Bayer and MOMA Therapeutics, Inc., a biopharmaceutical company in the clinical stage that focuses on discovering and creating precise therapeutics, have declared a collaboration. This partnership involves an option and exclusive license agreement...
, CDSCO.jpg)
